Normal view MARC view ISBD view

Second-Generation Drug-Eluting Resorbable Magnesium Scaffold: Review of the Clinical Evidence. [Review] - 2020

Available in print through MWHC library: 2002 - present

Since October 8, 2013, the second-generation drug-eluting resorbable magnesium scaffold (RMS) has been used to treat coronary lesions. At present, the second-generation drug-eluting RMS is clinically available in Europe, some South American countries, and some Asian and African countries. Furthermore, patients are currently being enrolled in ongoing post-marketing trials. This device has the potential to be an alternative to drug-eluting stents in the future, but there is not yet sufficient evidence. This review provides the latest available evidence, comparison with other bioresorbable scaffolds, future perspectives, and discussion of clinical case reports with second-generation drug-eluting RMS. SUMMARY: Favorable outcomes have been reported after second-generation drug-eluting RMS implantation. More long-term clinical outcomes for this novel device are still required in the future. Copyright (c) 2019 Elsevier Inc. All rights reserved.


English

ISSN: 1878-0938

Standard No.: 10.1016/j.carrev.2019.10.012 [doi] S1553-8389(19)30665-7 [pii]

Subjects--Topical Terms:
*Absorbable Implants
*Cardiovascular Agents/ad [Administration & Dosage]
*Coated Materials, Biocompatible
*Coronary Artery Disease/th [Therapy]
*Magnesium
*Percutaneous Coronary Intervention/mo [Mortality]
Animals
Cardiovascular Agents/ae [Adverse Effects]
Coronary Artery Disease/dg [Diagnostic Imaging]
Humans
Percutaneous Coronary Intervention/ae [Adverse Effects]
Prosthesis Design
Risk Factors
Treatment Outcome

Subjects--Geographic Terms:
MedStar Heart & Vascular Institute

Index Terms--Function:
Journal Article
Review